Knee OA can be prevented, but it requires modification of multiple behavioral factors, to prevent knee degeneration and dramatically improve overall health
Novo Nordisk, maker of #Wegovy, will be submitting the drug for regulatory approval in early 2026
The question isn't just "how much weight can we help patients lose?" but "how do we match the right therapy to the right patient at the right time?" The 28% weight loss is remarkable, but the higher discontinuation rates remind us that efficacy on paper doesn't always translate to real-world success
Researchers found that Valdecoxib (VAL) can inhibit inflammation and endoplasmic reticulum (ER) stress through AMPK-regulated HSPB1 pathway, thus improving skeletal muscle IR under hyperlipidemia
M-cells take up large antigens, macromolecular complexes, particulates, and proteins such as ferritin and peroxidase and also intact viruses, bacteria, and protozoa through a specific and regulated process termed receptor-mediated endocytosis in which cell-surface receptors such as GP2 recognize specific antigens expressed on microorganisms that initiate transit through the cell, exocytosis, and engulfment by phagocytic subepithelial dendritic cells (Fig
Because it degrades in blood in a pathway involving amino-peptidases, it may not be suitable for people who take medications that inhibit or are metabolized by peptidases (e.g., captopril, a treatment for hypertension).4 Also, based on what we know about other therapeutic peptides, we would say DSIP is contraindicated for women who are pregnant or breastfeeding as well as people with a personal history of cancer
